{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:19:10Z","timestamp":1764919150700,"version":"3.46.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide. CXCL12, a chemokine involved in tumor progression and metastasis, has been inconsistently associated with GC survival. This meta-analysis aimed to evaluate the prognostic significance of CXCL12 expression in GC patients. A comprehensive literature search was conducted in PubMed, Embase, and Web of Science. Observational studies assessing tumor CXCL12 expression and survival outcomes in GC patients were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model by incorporating heterogeneity. Ten studies comprising 1361 GC patients were included. High CXCL12 expression was significantly associated with poorer overall survival (OS) (HR: 1.85, 95% CI 1.51\u20132.26,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) with mild heterogeneity (\n                    <jats:italic>I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200917%). Subgroup analyses revealed that the association between high CXCL12 expression and OS was stronger in studies defining high expression as above the median density value (HR: 2.63, 95% CI 1.79\u20133.86) than in those using any positive expression (HR: 1.61, 95% CI 1.30\u20132.00;\n                    <jats:italic>p<\/jats:italic>\n                    for subgroup difference\u2009=\u20090.03). Additionally, a more pronounced association was observed in studies with follow-up durations\u2009\u2265\u200936\u00a0months (HR: 2.42, 95% CI 1.84\u20133.18) compared to those with\u2009&lt;\u200936\u00a0months (HR: 1.59, 95% CI 1.28\u20131.99;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03). The pooled results also indicated an association between high CXCL12 expression and worse progression-free survival (PFS) (HR: 1.52, 95% CI 1.05\u20132.20,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03). High CXCL12 expression is associated with poorer survival outcomes in GC patients.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01674-3","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:37:10Z","timestamp":1749271030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CXCL12 expression and the survival of patients with gastric cancer: a meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Jinxiu","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"1","key":"1674_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5230\/jgc.2025.25.e10","volume":"25","author":"SS Eom","year":"2025","unstructured":"Eom SS, Ryu KW, Han HS, Kong SH. A comprehensive and comparative review of global gastric cancer treatment guidelines: 2024 update. J Gastric Cancer. 2025;25(1):153\u201376. https:\/\/doi.org\/10.5230\/jgc.2025.25.e10.","journal-title":"J Gastric Cancer"},{"issue":"1","key":"1674_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"1674_CR3","doi-asserted-by":"publisher","first-page":"100845","DOI":"10.1016\/j.ctarc.2024.100845","volume":"41","author":"TI Mamun","year":"2024","unstructured":"Mamun TI, Younus S, Rahman MH. Gastric cancer\u2014epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: an updated review. Cancer Treat Res Commun. 2024;41:100845. https:\/\/doi.org\/10.1016\/j.ctarc.2024.100845.","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"1674_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/s24010037","volume":"24","author":"S Das","year":"2024","unstructured":"Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors. 2024;24(1):37.","journal-title":"Sensors"},{"issue":"4","key":"1674_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/cmi.2017.107","volume":"15","author":"R Janssens","year":"2018","unstructured":"Janssens R, Struyf S, Proost P. The unique structural and functional features of CXCL12. Cell Mol Immunol. 2018;15(4):299\u2013311. https:\/\/doi.org\/10.1038\/cmi.2017.107.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"1674_CR6","doi-asserted-by":"publisher","first-page":"C987","DOI":"10.1152\/ajpcell.00406.2006","volume":"292","author":"I Kryczek","year":"2007","unstructured":"Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1\/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 2007;292(3):C987\u201395. https:\/\/doi.org\/10.1152\/ajpcell.00406.2006.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1674_CR7","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","volume":"11","author":"Y Shi","year":"2020","unstructured":"Shi Y, Riese DJ 2nd, Shen J. The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;11:574667. https:\/\/doi.org\/10.3389\/fphar.2020.574667.","journal-title":"Front Pharmacol"},{"key":"1674_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cytogfr.2023.10.003","volume":"75","author":"DP Anastasiadou","year":"2024","unstructured":"Anastasiadou DP, Quesnel A, Duran CL, Filippou PS, Karagiannis GS. An emerging paradigm of CXCL12 involvement in the metastatic cascade. Cytokine Growth Factor Rev. 2024;75:12\u201330. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.10.003.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"1674_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/cam4.1085","volume":"6","author":"LJ Xue","year":"2017","unstructured":"Xue LJ, Mao XB, Ren LL, Chu XY. Inhibition of CXCL12\/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. Cancer Med. 2017;6(6):1424\u201336. https:\/\/doi.org\/10.1002\/cam4.1085.","journal-title":"Cancer Med"},{"key":"1674_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.matbio.2024.06.004","volume":"132","author":"P Li","year":"2024","unstructured":"Li P, Zhang H, Chen T, Zhou Y, Yang J, Zhou J. Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer. Matrix Biol. 2024;132:59\u201371. https:\/\/doi.org\/10.1016\/j.matbio.2024.06.004.","journal-title":"Matrix Biol"},{"issue":"11","key":"1674_CR11","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1245\/s10434-007-9521-6","volume":"14","author":"S Ishigami","year":"2007","unstructured":"Ishigami S, Natsugoe S, Okumura H, Matsumoto M, Nakajo A, Uenosono Y, et al. Clinical implication of CXCL12 expression in gastric cancer. Ann Surg Oncol. 2007;14(11):3154\u20138. https:\/\/doi.org\/10.1245\/s10434-007-9521-6.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1674_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3892\/ijo.2011.1044","volume":"39","author":"CC Schimanski","year":"2011","unstructured":"Schimanski CC, Jordan M, Schlaegel F, Schmidtmann I, Lang H, Galle PR, et al. SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer. Int J Oncol. 2011;39(2):515\u201320. https:\/\/doi.org\/10.3892\/ijo.2011.1044.","journal-title":"Int J Oncol"},{"issue":"3","key":"1674_CR13","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1007\/s12032-011-9990-0","volume":"29","author":"J Ying","year":"2012","unstructured":"Ying J, Xu Q, Zhang G, Liu B, Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol. 2012;29(3):1716\u201322. https:\/\/doi.org\/10.1007\/s12032-011-9990-0.","journal-title":"Med Oncol"},{"issue":"11","key":"1674_CR14","first-page":"6397","volume":"34","author":"T Masuda","year":"2014","unstructured":"Masuda T, Nakashima Y, Ando K, Yoshinaga K, Saeki H, Oki E, et al. Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. Anticancer Res. 2014;34(11):6397\u2013403.","journal-title":"Anticancer Res"},{"issue":"8","key":"1674_CR15","first-page":"4051","volume":"34","author":"H Satomura","year":"2014","unstructured":"Satomura H, Sasaki K, Nakajima M, Yamaguchi S, Onodera S, Otsuka K, et al. Can expression of CXCL12 and CXCR4 be used to predict survival of gastric cancer patients? Anticancer Res. 2014;34(8):4051\u20137.","journal-title":"Anticancer Res"},{"issue":"11","key":"1674_CR16","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/cas.12531","volume":"105","author":"X Wang","year":"2014","unstructured":"Wang X, Zhang H, He H, Shen Z, Tang Z, Xu J, et al. Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection. Cancer Sci. 2014;105(11):1447\u201356. https:\/\/doi.org\/10.1111\/cas.12531.","journal-title":"Cancer Sci"},{"issue":"5","key":"1674_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ijc.29864","volume":"138","author":"D Izumi","year":"2016","unstructured":"Izumi D, Ishimoto T, Miyake K, Sugihara H, Eto K, Sawayama H, et al. CXCL12\/CXCR4 activation by cancer-associated fibroblasts promotes integrin \u03b21 clustering and invasiveness in gastric cancer. Int J Cancer. 2016;138(5):1207\u201319. https:\/\/doi.org\/10.1002\/ijc.29864.","journal-title":"Int J Cancer"},{"issue":"1","key":"1674_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-021-01475-8","volume":"20","author":"D-L Chen","year":"2021","unstructured":"Chen D-L, Sheng H, Zhang D-S, Jin Y, Zhao B-T, Chen N, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer. 2021;20(1):166. https:\/\/doi.org\/10.1186\/s12943-021-01475-8.","journal-title":"Mol Cancer"},{"issue":"10","key":"1674_CR19","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.7150\/jca.49707","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin Y, Wang F, Ni H, Liu Y, Yin Y, Zhou X, et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J Cancer. 2021;12(10):3011\u201323. https:\/\/doi.org\/10.7150\/jca.49707.","journal-title":"J Cancer"},{"issue":"1","key":"1674_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/s12885-024-12302-w","volume":"24","author":"S Wang","year":"2024","unstructured":"Wang S, Zhang W, Wu X, Zhu Z, Chen Y, Liu W, et al. Comprehensive analysis of T-cell regulatory factors and tumor immune microenvironment in stomach adenocarcinoma. BMC Cancer. 2024;24(1):570. https:\/\/doi.org\/10.1186\/s12885-024-12302-w.","journal-title":"BMC Cancer"},{"key":"1674_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1674_CR22","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"1674_CR23","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration; 2021. www.training.cochrane.org\/handbook."},{"key":"1674_CR24","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2010. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"11","key":"1674_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"7109","key":"1674_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"11","key":"1674_CR27","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, Wang H, Ni Y, Liu Y, et al. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19(11):3341\u201359. https:\/\/doi.org\/10.7150\/ijbs.82317.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1674_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9(1):176. https:\/\/doi.org\/10.1038\/s41392-024-01868-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"33","key":"1674_CR29","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.2174\/0929867326666191113113110","volume":"27","author":"P Yang","year":"2020","unstructured":"Yang P, Hu Y, Zhou Q. The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer. Curr Med Chem. 2020;27(33):5543\u201361. https:\/\/doi.org\/10.2174\/0929867326666191113113110.","journal-title":"Curr Med Chem"},{"issue":"9","key":"1674_CR30","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745\u201370. https:\/\/doi.org\/10.1007\/s00018-019-03351-7.","journal-title":"Cell Mol Life Sci"},{"key":"1674_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4040036","author":"V Umansky","year":"2016","unstructured":"Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel). 2016. https:\/\/doi.org\/10.3390\/vaccines4040036.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"1674_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859\u201374. https:\/\/doi.org\/10.1016\/j.immuni.2021.01.012.","journal-title":"Immunity"},{"issue":"9","key":"1674_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.14670\/hh-27.1155","volume":"27","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Jo DY. The role of the CXCR4\/CXCL12 axis and its clinical implications in gastric cancer. Histol Histopathol. 2012;27(9):1155\u201361. https:\/\/doi.org\/10.14670\/hh-27.1155.","journal-title":"Histol Histopathol"},{"issue":"3","key":"1674_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/157489212801820039","volume":"7","author":"F de Nigris","year":"2012","unstructured":"de Nigris F, Schiano C, Infante T, Napoli C. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012;7(3):251\u201364. https:\/\/doi.org\/10.2174\/157489212801820039.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"1674_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030469","author":"JC L\u00f3pez-Gil","year":"2021","unstructured":"L\u00f3pez-Gil JC, Martin-Hijano L, Hermann PC, Sainz B Jr. The CXCL12 crossroads in cancer stem cells and their niche. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13030469.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1674_CR36","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","volume":"126","author":"JW Song","year":"2010","unstructured":"Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010;126(6):2234\u201342. https:\/\/doi.org\/10.1097\/PRS.0b013e3181f44abc.","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"1674_CR37","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.31557\/apjcp.2023.24.6.2121","volume":"24","author":"NS Gamal","year":"2023","unstructured":"Gamal NS, Ashraf S, Hesham N, Aboushousha T, Hegab F, Safwat G, et al. Immunohistochemical expression of CD90, CD133, and TPM1 in relation to gastric cancer and H. pylori association. Asian Pac J Cancer Prev. 2023;24(6):2121\u20137. https:\/\/doi.org\/10.31557\/apjcp.2023.24.6.2121.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"1674_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/jso.23127","volume":"107","author":"B Schmidt","year":"2013","unstructured":"Schmidt B, Yoon SS. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol. 2013;107(3):259\u201364. https:\/\/doi.org\/10.1002\/jso.23127.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1674_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10120-023-01424-y","volume":"27","author":"F Lordick","year":"2024","unstructured":"Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, et al. German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 2024;27(1):6\u201318. https:\/\/doi.org\/10.1007\/s10120-023-01424-y.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1674_CR40","doi-asserted-by":"publisher","first-page":"e0075121","DOI":"10.1128\/mSphere.00751-21","volume":"6","author":"D Kashyap","year":"2021","unstructured":"Kashyap D, Baral B, Jakhmola S, Singh AK, Jha HC. Helicobacter pylori and Epstein-Barr Virus coinfection stimulates aggressiveness in gastric cancer through the regulation of gankyrin. mSphere. 2021;6(5):e0075121. https:\/\/doi.org\/10.1128\/mSphere.00751-21.","journal-title":"mSphere"},{"issue":"1","key":"1674_CR41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","volume":"7","author":"Z-N Lei","year":"2022","unstructured":"Lei Z-N, Teng Q-X, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7(1):358. https:\/\/doi.org\/10.1038\/s41392-022-01190-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1674_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/jlb.2bt1018-715rr","volume":"109","author":"GD Luker","year":"2021","unstructured":"Luker GD, Yang J, Richmond A, Scala S, Festuccia C, Schottelius M, et al. At the bench: pre-clinical evidence for multiple functions of CXCR4 in cancer. J Leukoc Biol. 2021;109(5):969\u201389. https:\/\/doi.org\/10.1002\/jlb.2bt1018-715rr.","journal-title":"J Leukoc Biol"},{"issue":"6","key":"1674_CR43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878\u201385. https:\/\/doi.org\/10.1038\/s41591-020-0880-x.","journal-title":"Nat Med"},{"issue":"6","key":"1674_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/s1470-2045(18)30147-5","volume":"19","author":"S Pernas","year":"2018","unstructured":"Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018;19(6):812\u201324. https:\/\/doi.org\/10.1016\/s1470-2045(18)30147-5.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01674-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:13Z","timestamp":1764917173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01674-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01674-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Institutional Review Board approval was not required because this is a meta-analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"191"}}